International Asthma Conference at Nemacolin
0

CME Overview

The World’s Leading Asthma Experts

Conference Overview

Despite significant advances in our understanding of the pathophysiology and treatment of asthma, and the availability of national and international guidelines on the diagnosis and treatment of asthma, recent surveys show that asthma control and morbidity have not improved. Research is being conducted to address many of these issues. This conference will bring the latest research developments in this rapidly changing field to health care professionals practicing, researching, and teaching asthma care.

Asthma exists in diverse environments and populations and varies in severity by time and patient. Moreover, based on the results of recent research, asthma is being viewed less as a disease and more as a syndrome with multiple phenotypes and endotypes. The resultant heterogeneity forms the basis for the education and discussion embedded in the International Asthma Conference at Nemacolin, which takes pride in being one of the only conferences in the world dedicated exclusively to asthma. Its purpose is to create a highly interactive educational environment, including the world’s best asthma researchers, teachers, and clinicians, to critique cutting-edge research and translate key research findings into clinical pearls that will benefit patients with asthma.

 

Target Audience and Learning Objectives

Target Audience:

  • All practicing allergists/immunologists and pulmonologists

  • Fellows in allergy/immunology and pulmonary training programs

  • Primary care physicians who care for asthma patients

  • Allied health professionals with interest in asthma

Following this conference, participants should be able to:

  • Characterize and quantify asthma disparities in rural areas and identify solutions to address asthma disparities in rural areas.

  • Discuss the effects of respiratory viruses on airway nerves and nerve-related channels and receptors.

  • Identify implications for the pathogenesis of TH2-low and TH2-high asthma.

  • Evaluate the pathobiology of eosinophils.

  • Evaluate the efficacy of anti-eosinophilic treatments in atopic dermatitis; chronic cough; eosinophilic esophagitis; and asthma.

  • Describe what has been learned about the role and function of eosinophils.

  • Evaluate the potential for the use of novel, non-asthma medications as asthma treatments.

  • Evaluate the potential for treatment approaches for adult asthma to work in children as well.

  • Identify similarities and differences in disease remission for asthma and atopic dermatitis.

  • Recognize how AI can be utilized to advance asthma research.

  • Recognize how large language models can be utilized to improve asthma care.

  • Re-imagine the definition of severe asthma to promote care.

  • Identify the various definitions of asthma remission and examine whether any asthma medications have enabled asthma remission.

  • Identify key elements of a corticosteroid stewardship program and describe the unique need for corticosteroid stewardship in children.

  • Discuss corticosteroid-sparing strategies.

  • Describe how new methods could be used in the assessment and management of asthma exacerbations in children.

  • Indicate systems that help transition adolescents with asthma from pediatric to adult care management.

  • Provide a model for supporting the care of children with asthma in their community setting.

 

Intended Outcome

To positively impact the morbidity and cost of asthma by providing health care practitioners with recommendations on the care of patients with asthma that are based on the most up-to-date research conducted by the world’s leading asthma experts.

 

Accreditation Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the WVU School of Medicine and Maci’s Teams. The WVU School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The WVU Office of CME designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physicians
West Virginia University Office of Continuing Education will confirm participation in this educational activity.

Disclosure
It is the policy of the WVU School of Medicine Office of CME to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/authors/planners participating in our programs are expected to disclose any relevant relationships they may have with commercial companies.

For this conference, Drs Akuthota, Anderson, Beck, Busse, Cahill, Georas, Lugogo, Navanandan, O'Byrne, Panettieri, Pongdee, A. ‎Ray, M. Ray, Satia, Spergel, Szefler, and Wenzel will disclose the relevant relationships with commercial companies. All others have indicated they have no relevant interests to disclose.

The relationships, along with the educational content of this program, have been reviewed and any potential conflicts of interest have been resolved to the satisfaction of the WVU School of Medicine Office of CME.

Praveen Akuthota, MD
Sanofi, Consulting fee (through university contract), Consultant, Relevant
Sanofi, Research Grant, In-Kind Drug, Site PI; PI for Investigator-Initiated Research, Relevant
Grants or contracts from Sanofi, AstraZeneca, Recode, and 4D Molecular Therapeutics as site PI. These relationships are not terminated.
Consulting fees from AstraZeneca (via university contract, ongoing), GSK (terminated), Connect Biopharma (ongoing), Amgen (terminated), Sanofi (via university contract, ongoing), Vida Ventures (terminated), Enveda (terminated), General Medicines (terminated), Apogee Therapeutics (terminated), Johnson & Johnson (terminated) and Gilead (ongoing).

William C. Anderson III, MD
Sanofi, Honorarium, Advisory Board Member, terminated, not relevant
Regeneron, Research Collaborator, not relevant
Teva: Honorarium, Research Advisory Board Member, Terminated, Not relevant; Colorado Medicaid Supplemental Funding Program: Clinical Program Development Support, PI, not terminated, not relevant

Lisa A. Beck, MD
Abbvie, Honoraria, consultant, ongoing, relevant
Amgen, honoraria, consultant, ongoing, relevant
Consultant or on an Advisory Board for the following additional companies that are mostly asking my opinion about drugs in development to treat atopic dermatitis, chronic urticaria or prurigo nodularis. I have been paid honoraria for this effort. The additional companies are: Apogee, Arcutis, Astra Zeneca, Bambusa Therapeutics Inc, Belharra Therapeutics, Dermavent, Eli Lilly and Company, Galderma, Gilead, GlaxoSmithKline, Janssen, Merck, Mestag Therapeutics, North Immunology, Novartis, Phylaxis, Pfizer, Poplar Therapeutics, Rapt Therapeutics, Regeneron Pharmaceuticals Inc., ResVitaBio, Inc., Sanofi-Aventis/Genzyme, Sitryx Therapeutics, Stealth BioTherapeutics, TRex Bio, Inc, Triveni Bio, UCB Pharma, Union Therapeutics and Zai Laboratory.

William W. Busse, MD
Sanofi, Consulting fees, Consultant, ongoing not relevant
GlaxoSmithKline, Honorarium, Speaker, ongoing, not relevant
Regeneron, Consultant, Consulting fees, the relationship has not terminated.

Katherine N. Cahill, MD
Sanofi, Consultancy fees, Advisory Board Member, ongoing, not relevant
AstraZeneca, Consultancy Fee, Advisory Board Member, ongoing, not relevant
Eli Lilly, consultancy fee, consultant, terminated
Eli Lilly, research funding, principal investigator, ongoing
Bohringer Ingelheim, consultancy fee, advisory board member, ongoing
Novo Nordisk, research support, principal investigator, ongoing
UpToDate, royalties, author, ongoing

Steve N. Georas, MD
No personal relevant relationships disclosed. Disclosed relevant spouse’s relevant relationships – See Dr. Lisa Beck disclosure

Njira L. Lugogo, MD
AbbVie, Consulting Fees, Consultant, ongoing, not relevant
Amgen, Consulting fees, Advisor, speaker at conference with my own content, ongoing, not relevant
NLL received consulting fees from AbbVie, Amgen, Apogee, AstraZeneca, Avillion, Chiesi, Foresee, Genentech, GSK, Inctye, Johnson & Johnson, Niox, Novartis, Pfizer, Pharmosa, Regeneron, Sanofi, and Teva; honoraria for non-speakers bureau presentations from GSK, TEVA, SANOFI/Regeneron and Astra Zeneca; and travel support from Astra Zeneca, SANOFI, TEVA, Regeneron and GSK; her institution received research support from Amgen, AstraZeneca, Avillion, Bellus, Evidera, Gossamer Bio, Genentech, GSK, Janssen, Pfizer, Regeneron, Roche, Sanofi, Novartis, Teva and WinWard Bio. She is an honorary faculty member of Observational and Pragmatic Research Institute (OPRI) but does not receive compensation for this role. All relationships are ongoing and non of them are pertinent to the topic of my presentation

Nidhya Navanandan, MD, MSCS
Aerogen Limited, Honorarium, Consultant, ongoing, not relevant

Paul M. O'Byrne, MB, FRCP(C), FRSC
AstraZeneca, Honorarium; Grant in Aid, Advisor; PI, ongoing, relevant
GSK, Honorarium, Advisor; Speaker, ongoing, relevant
Sanofi/Regeneron: Speaker; current
Novartis: Grant in Aid; terminated
Jasper: Grant in Aid: terminated
Arrowhead: Grant in Aid: current

Reynold A. Panettieri, Jr., MD
AstraZeneca, GSK, Sanofi, RIFM, Regeneron, honorarium, consultant/Ad Board, ongoing, relevant
AstraZeneca, GSK, Medimmune, ConnectBio, RIFM, Agomab, Genentech, Haleon, research grant, PI, ongoing, relevant
AstraZeneca, Regeneron, Sanofi, GSK, honorarium, Speaker, ongoing

Thanai Pongdee, MD
Sanofi, research funding, researcher, ongoing, not relevant
Blueprint Medicines, research funding, researcher, ongoing, not relevant
Cogent Biosciences: honorarium, advisory board, relationship ongoing, not relevant

Anuradha Ray, PhD
Expedition Therapeutics, Consultant, ongoing, not relevant

Mondira Ray, MD, MBI
OpenEvidence Inc., Salary and equity, Full-time employee, ongoing, relevant

Imran Satia, MA, MB, BChir (cantab), PhD, MRCP, FACP
GSK, Honorarium, Speaker, Consulting, ongoing, relevant
AstraZeneca, Honorarium, Speaker, ongoing, not relevant
I.S is supported by the Canada Research Chair program and reports grants from Merck, MITACS, GSK, Bellus, Trevi Therapeutics, Bayer and Genentech, consultancy fees from Merck, GSK, Bellus, Sanofi-Regeneron and Methapharm and payment or honoraria for lectures, presentations, manuscript writing 

Jonathan M. Spergel, MD, PhD
Sanofi, Grant Support, Investigator, ongoing, not relevant
Regeneron, Grant Support, Investigator, ongoing, not relevant
ARS Pharma-investigator, ongoing, not related
Novartis-investigator, ongoing not related
Kymera-consultant, ongoing, not related

Stanley J. Szefler, MD
Astra Zeneca, stipend for one meeting paid to my University, consultant, terminated, not relevant

Sally E. Wenzel, MD
Chiesi, honorarium, Consultant, ongoing, relevant
Johnson and Johnson, honorarium, Consultant, ongoing, not relevant
Kymera. Consultant cash ended
Eli Lilly. Consultant Cash ended
Aer Therapeutics Ad board. stock ongoing.
Regeneron. investigator initiated study laboratory support. ongoing

Commercial Support
A special thank you to our sponsors/exhibitors: Accredo Specialty, AstraZeneca, BioCryst, Genentech, GSK, Ionis, Maci’s TEAMS, and Sanofi | Regeneron

Contact
Please contact Jessica Bolton if you have any questions (jbolton@macisteams.org).